Financials in USD. Standardized financial statements.
A compact view of how Karyopharm Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $146.07M | $145.24M | $146.03M | $157.07M | $209.82M | $108.08M | $40.89M | $30.34M | $1.60M | $154,000 |
| Revenue Growth? | +0.6% | -0.5% | -7.0% | -25.1% | +94.1% | +164.3% | +34.8% | +1790.1% | +942.2% | 0.0% |
| Cost of Revenue? | $5.95M | $6.01M | $4.94M | $5.21M | $3.40M | $2.71M | $2.41M | $161.37M | $107.27M | $86.94M |
| Gross Profit? | $140.12M | $139.23M | $141.09M | $151.86M | $206.42M | $105.38M | $38.49M | -$131.04M | -$105.67M | -$86.78M |
| Gross Margin? | +95.9% | +95.9% | +96.6% | +96.7% | +98.4% | +97.5% | +94.1% | -431.9% | -6583.7% | -56353.2% |
| Operating Expenses? | $230.82M | $258.67M | $270.63M | $294.06M | $304.69M | $277.23M | $227.76M | $210.22M | $132.14M | $110.89M |
| Operating Income? | -$90.71M | -$119.44M | -$129.54M | -$142.20M | -$98.27M | -$171.85M | -$189.28M | -$179.88M | -$130.54M | -$110.73M |
| EBITDA? | -$149.85M | -$38.60M | -$118.42M | -$139.31M | -$96.98M | -$167.85M | -$182.93M | -$175.15M | -$128.21M | -$108.72M |
| Income Before Tax | -$196.00M | -$76.36M | -$142.78M | -$164.92M | -$123.82M | -$195.96M | -$199.55M | -$178.38M | -$128.92M | -$109.44M |
| Income Tax Expense | $43,000 | $57,000 | $323,000 | $369,000 | $268,000 | $309,000 | $40,000 | $26,000 | $63,000 | $139,000 |
| Net Income? | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -$124.09M | -$196.27M | -$199.59M | -$178.41M | -$128.98M | -$109.58M |
| EPS? | $-17.93 | $-9.41 | $-18.79 | $-30.28 | $-24.75 | $-40.87 | $-48.32 | $-47.11 | $-42.15 | $-43.80 |
| Diluted EPS? | $-17.93 | $-9.41 | $-18.79 | $-30.28 | $-24.75 | $-40.87 | $-48.32 | $-47.11 | $-42.15 | $-43.80 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality